International Journal of Drug Policy最新文献

{"title":"Stronger isn't always better: Nalmefene in community overdose response and the false promise of quick-fix public health solutions.","authors":"Mark C Navin, Lauren R Fink, Travis N Rieder","doi":"10.1016/j.drugpo.2025.104945","DOIUrl":"https://doi.org/10.1016/j.drugpo.2025.104945","url":null,"abstract":"<p><p>The United States is in its third decade of a drug overdose crisis. An important tool for responding to this crisis is the opioid overdose reversal agent, naloxone. However, with hyper-potent opioids like fentanyl present in the drug supply, some have argued for alternative overdose reversal agents such as nalmefene, which has higher opioid receptor affinity and a longer half-life. This reasoning moves too quickly. There is little evidence that adopting nalmefene for community-based overdose response will provide overall benefit, and there are good reasons to expect that it will cause substantial harm. Nalmefene appears to promise a \"magic bullet\" solution to a complicated and terrible problem, but sustainable overdose prevention requires comprehensive improvements to public health infrastructure. The overdose crisis requires attention, effort, and funding more than it needs a novel technological or pharmaceutical intervention.</p>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"145 ","pages":"104945"},"PeriodicalIF":4.4,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why are people with lived and living experience conflicted about the legalisation of drugs? Analysing qualitative data from the UK Drug Policy Voices project using Schwartz’s theory of basic values","authors":"Rebecca Askew ,&nbsp;Alison Ritter","doi":"10.1016/j.drugpo.2025.104936","DOIUrl":"10.1016/j.drugpo.2025.104936","url":null,"abstract":"<div><h3>Introduction</h3><div>Emerging research on values and moralities in drug policy research indicates that policy may become stuck because of value conflicts and tensions. To develop new knowledge in this area, this paper seeks to identify the values that emerged in discussions amongst people with lived and living experience about the legalisation of drugs; and examine the relationships between value positions, synergies and tensions within dialogue about legalisation.</div></div><div><h3>Methods</h3><div>The data derived from the qualitative research collected for the UK Drug Policy Voices project and included workshop, creative and interview data. All dialogue that emerged in reference to legalisation was coded against Schwartz’s ten basic values, which Schwartz presents as a circumplex where values close to one another are complimentary and values opposing one another represent value conflict. The findings structure around two sections, the first demonstrating value tensions and complexity, and the second how value clusters emerged in the dialogues around three legalisation architectures: state regulation, commercial regulation, and social justice models.</div></div><div><h3>Results</h3><div>The narratives were complex, overlapping and represented dialectical rather than dichotomous opinions. Security, self-direction, conformity, universalism, benevolence, power and achievement values underpin complex narrations of legalisation. Our analyses suggest a pattern whereby strict regulation models were underpinned by security and conformity values; universalism and benevolence values were the foundation of social justice approaches, and commercial models were driven by self-direction, power and achievement values. Value tensions surfaced when opposing values in the circumplex surfaced together within a narrative, for example between self-direction and conformity, and universalism and power.</div></div><div><h3>Discussion</h3><div>Through its focus on surfacing values, this paper illuminates new knowledge on the complexities that lie behind drug policy debates. Firstly, multiple values are held at once, which are often in conflict; secondly, there are distinct value clusters that underpin different architectures of legalisation; and thirdly, the same value can both support and challenge legalisation approaches. This paper highlights that participants were conflicted about legalisation due to its potential variegated impact on people, groups and communities, demonstrating that lived and living experience embodies more than personal consumption patterns.</div></div><div><h3>Conclusion</h3><div>Debates about legalisation are complex and conflicted due to value pluralism and value conflict. Multiple values were activated when considering legalisation from the position of one’s own drug use, family and friends, and the community.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"145 ","pages":"Article 104936"},"PeriodicalIF":4.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined response to commentaries regarding Ivasiy et al. (2025)","authors":"Roman Ivasiy ,&nbsp;Lynn M. Madden ,&nbsp;Kimberly A. Johnson ,&nbsp;Eteri Machavariani ,&nbsp;Bachar Ahmad ,&nbsp;David Oliveros ,&nbsp;Jiale Tan ,&nbsp;Natalie Kil ,&nbsp;Frederick L. Altice","doi":"10.1016/j.drugpo.2025.104935","DOIUrl":"10.1016/j.drugpo.2025.104935","url":null,"abstract":"","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"145 ","pages":"Article 104935"},"PeriodicalIF":4.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis trading on Telegram channels: implications for the normalization of use and supply","authors":"Yifat BenBaruch ,&nbsp;Monica J. Barratt ,&nbsp;Daniel Feingold ,&nbsp;Sharon R. Sznitman","doi":"10.1016/j.drugpo.2025.104930","DOIUrl":"10.1016/j.drugpo.2025.104930","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Telegram, an encrypted messaging app, has become a platform for cannabis supply through dedicated trading groups. This study examines how retailers use Telegram for cannabis distribution and explores its potential role in normalizing cannabis use and supply. We aim to understand how these trading groups may be reshaping drug markets and influencing cannabis normalization processes.</div></div><div><h3>Method</h3><div>A digital ethnographic approach was used to analyze 20 Israeli Telegram cannabis trading groups, with over 1000 members each. Data from 521 cannabis ads posted between April and May 2022 were thematically analyzed using an open coding approach.</div></div><div><h3>Results</h3><div>The analysis revealed two key normalization processes: normalization of cannabis use through increased accessibility, knowledge dissemination, and medicalization, and normalization of cannabis supply through conventional marketing strategies combined with relationship-focused approaches that resonate with social supply elements.</div></div><div><h3>Conclusions</h3><div>Various forms of cannabis normalization processes are visible in Telegram-facilitated cannabis trade. This may have public health implications as it may be related to increasing cannabis use across diverse populations. However, normalization through Telegram may simultaneously provide users with detailed product information, promote informed decision-making, and encourage indigenous harm-reduction strategies. This paradoxical impact underscores the need for nuanced policy frameworks that address both the risks and the harm reduction opportunities inherent in knowledge-driven digital cannabis markets.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"145 ","pages":"Article 104930"},"PeriodicalIF":4.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144779301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting extended-release buprenorphine data: The importance of specifying formulations and accurately representing prior evidence","authors":"Michelle R. Lofwall ,&nbsp;Natalie R. Budilovsky-Kelley","doi":"10.1016/j.drugpo.2025.104934","DOIUrl":"10.1016/j.drugpo.2025.104934","url":null,"abstract":"","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"145 ","pages":"Article 104934"},"PeriodicalIF":4.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144771894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of dynamic recovery identity on lapse risk and the role of daily recovery meetings","authors":"Joseph H. Lancaster ,&nbsp;Timothy R. Brick ,&nbsp;H. Harrington Cleveland","doi":"10.1016/j.drugpo.2025.104941","DOIUrl":"10.1016/j.drugpo.2025.104941","url":null,"abstract":"<div><h3>Aims</h3><div>The social identity model of recovery (SIMOR) posits that adopting an identity affiliated with recovery (recovery identity) improves substance use disorder (SUD) outcomes. Although recovery identity has been investigated as a construct that is either static or slowly changing, evidence exists that it can change from one day to the next. The present study uses data drawn from a daily diary study on recovery community centers (RCCs) to examine the within-person association between recovery identity and drug craving, a key indicator of lapse risk. Seeing that social contact with recovery groups should increase the salience of recovery identity, we investigated the role of attending recovery meetings on the same-day association between recovery identity and craving.</div></div><div><h3>Methods</h3><div>Daily diary surveys were administered for 10 nights to 94 visitors of Pennsylvania RCCs. Nightly reports of recovery identity, craving, and daily recovery meeting attendance were analyzed using two-part random effects modeling to examine within-person associations between recovery identity and drug craving with recovery meetings as a moderator.</div></div><div><h3>Results</h3><div>Recovery identity was unrelated to the odds of craving occurring at the within-person level (<em>b</em> = 0.01, <em>SE</em> = 0.01, <em>n.s.</em>). On days when participants reported a craving, however, the extent of craving was significantly related to the level of recovery identity reported. Moreover, this same-day association between recovery identity and craving was moderated (strengthened) by same-day recovery meeting attendance, although only among days craving was reported (<em>b</em> = -0.04, <em>SE</em> = 0.02, <em>p</em> = .046). At the person level, recovery identity predicted both the extent (<em>b</em> = -0.06, <em>SE</em> = 0.015, <em>p</em> &lt; .001) and existence (<em>b</em> = 0.05, <em>SE</em> = 0.007, <em>p</em> &lt; .001) of craving. Contrary to hypotheses, the odds of experiencing craving were actually higher for those with a stronger recovery identity.</div></div><div><h3>Conclusions</h3><div>Based on these results, not only does stronger recovery identity appear to be associated with a reduction in craving at the within-person level, but the association may depend on same-day social contact with other recovering individuals as indicated by attending recovery support meetings. These findings not only underscore the value in examining recovery identity as dynamic but also highlight the dependence of the within-person dynamics between recovery-related intrapersonal states on daily behaviors. The counterintuitive finding at the person level may indicate a tendency for recovering individuals who experience cravings to invest in their recovery identity as a protective mechanism against relapse, although further research is needed to draw firm conclusions.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"145 ","pages":"Article 104941"},"PeriodicalIF":4.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient preferences for simplified hepatitis C testing modalities among people at risk of hepatitis C infection in Australia: the SELECT study","authors":"Annabelle Stevens ,&nbsp;Jake Abbott ,&nbsp;Loriate Gribbin ,&nbsp;Sarah Ahmed ,&nbsp;Mark Montebello ,&nbsp;Peter Ellis-Jones ,&nbsp;Thao Lam ,&nbsp;Meryem Jefferies ,&nbsp;Mim O’Flynn ,&nbsp;Joss O’Loan ,&nbsp;Alex Wade ,&nbsp;Anita Hoskins ,&nbsp;Laura Johnson ,&nbsp;Amie Johns ,&nbsp;Victoria Cock ,&nbsp;Mary E. Harrod ,&nbsp;David Silk ,&nbsp;Alison D. Marshall ,&nbsp;Gregory J. Dore ,&nbsp;Jason Grebely ,&nbsp;Evan B. Cunningham","doi":"10.1016/j.drugpo.2025.104871","DOIUrl":"10.1016/j.drugpo.2025.104871","url":null,"abstract":"<div><h3>Background</h3><div>Understanding patient preferences for hepatitis C virus (HCV) testing is essential to improve uptake and support elimination efforts. Despite innovative testing modalities, limited research examines how preferences influence testing choices. This study compared the uptake of HCV testing modalities when participants were given a choice.</div></div><div><h3>Methods</h3><div>People at risk of HCV were recruited from community sites in the Australian Hepatitis C Point-of-Care Testing Program. Participants used a visual aid outlining test features, including time to result and collection methods. Those reporting prior HCV infection were offered staff-assisted HCV RNA tests [point-of-care Xpert^Ⓡ HCV Viral Load Fingerstick (result in 60 min) or dried blood spot (DBS) (1–2 weeks)]. Participants without prior HCV infection were offered self-administered INSTI^Ⓡ HCV antibody (1 min), staff-assisted INSTI^Ⓡ HCV antibody (1 min), staff-assisted Bioline^Ⓡ HCV antibody (5–20 min), and HCV RNA tests. Participants completed their preferred test, a survey, and received AUD$20 reimbursement. Logistic regression evaluated factors associated with preference for point-of-care RNA testing in those with and without prior HCV infection.</div></div><div><h3>Results</h3><div>404 people were enrolled (27% female, 75% ever injected drugs). Among those with a history of HCV (<em>n</em>=129), 91% (<em>n</em>=117) selected point-of-care RNA testing and cited the short time to result (52%) and wanting to find out the RNA result today (21%) as key reasons. Among those without a history of HCV (<em>n</em>=275), 72% (<em>n</em>=199) selected staff-assisted INSTI^Ⓡ antibody testing, 19% (<em>n</em>=51) selected point-of-care RNA testing, and 4% (<em>n</em>=10) chose self-administered INSTI^Ⓡ antibody testing. Key reasons for selecting staff-assisted INSTI^Ⓡ included short time to result (75%) and reduced clinic time (8%). Factors associated with selecting point-of-care RNA testing among those without prior infection included recent injecting drug use, homelessness and recent opioid agonist therapy.</div></div><div><h3>Conclusion</h3><div>Findings highlight the importance of offering rapid, staff-assisted HCV testing to improve uptake among at-risk populations.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104871"},"PeriodicalIF":4.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From punishment to protection: Addressing drug-use stigma through human rights law in the Philippine context","authors":"Roy N. Villalobos","doi":"10.1016/j.drugpo.2025.104940","DOIUrl":"10.1016/j.drugpo.2025.104940","url":null,"abstract":"","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"145 ","pages":"Article 104940"},"PeriodicalIF":4.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: a Survey Based Experiment","authors":"K. Hitchins,&nbsp;J.P. Reynolds","doi":"10.1016/j.drugpo.2025.104909","DOIUrl":"10.1016/j.drugpo.2025.104909","url":null,"abstract":"<div><h3><em>Background</em></h3><div>Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently illegal in the UK. Less is known about how people form their attitudes towards psilocybin policies.</div></div><div><h3><em>Objectives</em></h3><div>To explore whether beliefs about the benefits and safety of psilocybin influence support for psilocybin policies.</div></div><div><h3><em>Methods</em></h3><div>In an online survey experiment, 804 participants were randomised to receive one of four interventions in a 2 (no information vs evidence for psilocybin benefits) x 2 (no information vs evidence for psilocybin safety) design. Public support for four psilocybin policies and beliefs about the benefits and safety of psilocybin were measured before and after participants were randomised to a group.</div></div><div><h3><em>Results</em></h3><div>In a two-way ANCOVA, the Benefits Intervention significantly increased policy support overall (<em>d</em> = 0.11, <em>p</em> &lt; .001); and for two of four psilocybin policies when analysed separately. Furthermore, the Benefits Intervention significantly strengthened beliefs that psilocybin is beneficial (<em>d</em> = 0.44, <em>p</em> &lt; .001) and safe (<em>d</em> = 0.26, <em>p</em> &lt; .001). The Safety Intervention increased psilocybin policy support overall (<em>d</em> = 0.10, <em>p</em> = .003); and for three of four psilocybin policies when analysed separately. The Safety Intervention also strengthened beliefs that psilocybin is safe (<em>d</em> = 0.28, <em>p</em> &lt; .001) but not that it is beneficial.</div></div><div><h3><em>Conclusions</em></h3><div>Communicating the benefits and safety of psilocybin can increase psilocybin policy support and strengthen beliefs about psilocybin, however further research is needed to explore the longevity of these results.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"143 ","pages":"Article 104909"},"PeriodicalIF":4.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug decriminalization policy under the microscope in the United States: crime data considerations to inform future research","authors":"Hope M. Smiley-McDonald ,&nbsp;Barrot H. Lambdin ,&nbsp;Pamela K. Lattimore ,&nbsp;Ian A. Silver ,&nbsp;Mark W. Pope ,&nbsp;Sean E. Wire ,&nbsp;Alex H. Kral","doi":"10.1016/j.drugpo.2025.104932","DOIUrl":"10.1016/j.drugpo.2025.104932","url":null,"abstract":"<div><div>When voters passed the 2020 Ballot Measure 110 (M110), the U.S. State of Oregon changed course from a criminal legal system response to a health-centered approach to substance use. M110 was passed with the goal of making health assessment screenings, treatment, and recovery services for substance use disorder available to all who need them and reduce the harms associated with involving the criminal legal system for people who use drugs. Although drug decriminalization was enacted in February 2021, most of M110’s funding streams for substance use disorder treatment, harm reduction, and housing assistance were delayed until August 2022. In the absence of health- or treatment-related data, preliminary studies used pre- and post-crime trend data to show that possession of controlled substances arrests decreased after Oregon implemented drug decriminalization.</div><div>The goal of this methods piece is to inform researchers and governments about the nuances of crime data when these data are often the only means available to assess a new drug policy. Given the multiple factors that occurred immediately before or contemporaneous to enactment of M110 (e.g., the COVID-19 pandemic, Oregon’s acute affordable housing shortage), we consider the methodological issues of prematurely attempting to answer research questions using available crime trend data and associated analytic models to make determinations about whether M110 was meeting its intended goals. Patience and time are needed for ensuring that the necessary and appropriate data are available that correspond to policy goals. We include recommendations for future analyses when more robust data are available to holistically assess the impacts of drug policies.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"145 ","pages":"Article 104932"},"PeriodicalIF":4.4,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}